A comprehensive systematic review published in The Lancet Healthy Longevity has found inconsistent evidence supporting the widespread health claims surrounding NAD+ (nicotinamide adenine dinucleotide) supplements, challenging the billion-dollar industry’s marketing promises. The review examined multiple clinical trials involving NAD+ precursors like nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), revealing a disconnect between the supplements’ popularity and their proven clinical benefits.
NAD+ is a crucial coenzyme involved in cellular energy metabolism and DNA repair that naturally declines with age. This biological fact has fueled intense consumer interest in NAD+ boosting supplements, with manufacturers claiming benefits ranging from enhanced energy and athletic performance to longevity and cognitive function. However, the systematic review found that while these supplements successfully raise NAD+ levels in the blood, this increase doesn’t consistently translate into meaningful health improvements across clinical endpoints.
The researchers noted significant variability in study designs, dosing regimens, and outcome measures, making it difficult to draw definitive conclusions about efficacy. Some trials showed modest improvements in specific markers like insulin sensitivity or muscle function in particular populations, while others demonstrated no significant benefits compared to placebo. The review particularly highlighted the lack of long-term safety data and standardized protocols for NAD+ supplementation research.
For consumers who have embraced NAD+ supplements—often at premium prices exceeding $50-100 monthly—these findings suggest a more cautious approach may be warranted. The review underscores the need for larger, well-designed clinical trials before NAD+ supplementation can be confidently recommended for anti-aging or health optimization purposes. Healthcare providers should counsel patients that while NAD+ precursors appear generally safe in short-term studies, the evidence for their purported benefits remains preliminary and mixed, falling short of the certainty suggested by aggressive marketing campaigns in the longevity and wellness sectors.
